Understanding Necrobiosis Lipoidica: A Chronic Skin Condition

Necrobiosis lipoidica is a rare, granulomatous skin disease whose exact cause remains unknown, but its strong ties to diabetes mellitus—especially type 1—are well established. The condition typically shows up as well-defined, yellowish-brown, atrophic plaques with a waxy look, most often on the shins. Lesions can be single or multiple, and they often have a shiny, telangiectatic surface with a violet-colored border. Over time, the center may become depressed and scar-like, making the skin fragile and prone to ulceration after even minor bumps or scrapes. The clinical course varies; some patients see spontaneous remission, while others face progressive enlargement and ulceration that can be tough to manage.

The underlying process involves a mix of microangiopathy, collagen degeneration, and a granulomatous inflammatory response. In people with diabetes, poor blood sugar control is thought to contribute to the development and progression of lesions. However, necrobiosis lipoidica also occurs in people without diabetes, which points to other factors—most notably smoking—playing a major role. This article examines how smoking affects the progression and management of necrobiosis lipoidica and offers evidence-based strategies for better patient outcomes.

Epidemiology and Clinical Significance

Necrobiosis lipoidica affects roughly 0.3% of the diabetic population, with a female predominance and a peak onset between the third and fifth decades of life. While not life-threatening, the condition can cause significant cosmetic disfigurement, pain, and functional impairment when ulceration sets in. Ulcers develop in about 25–35% of cases and are notoriously slow to heal, often leading to secondary infections and, in severe cases, squamous cell carcinoma. Given the chronic relapsing nature, effective management requires addressing both local skin pathology and systemic contributing factors such as smoking. The economic burden is also notable: frequent dermatology visits, wound care supplies, and lost productivity add up, especially in smokers whose disease is more aggressive.

Association with Diabetes

Between 60–65% of patients with necrobiosis lipoidica have diabetes, and roughly 15–20% will develop diabetes later in life. The relationship is not simply correlative; diabetic microangiopathy—marked by thickening of capillary basement membranes—leads to reduced oxygen delivery and impaired nutrient exchange, which likely contributes to the necrobiotic changes in the dermis. Poor glycemic control is linked to more extensive and ulcerated lesions. But even with optimal diabetes management, skin lesions may persist, highlighting the need for additional therapeutic targets. This persistence is especially common in patients who smoke, as the harmful effects of tobacco compounds add to the microvascular damage already present.

Prevalence and Demographics

Beyond diabetes, necrobiosis lipoidica occurs in about 0.1–0.3% of the general population. Smoking rates among patients with necrobiosis lipoidica are higher than in the general dermatology clinic population, suggesting a possible causative or contributory role. A 2018 retrospective study found that over 40% of patients with necrobiosis lipoidica were current smokers, compared to about 20% in age-matched controls. Women are affected more often than men, and the condition is more common in Caucasians. These demographic patterns reinforce the need to screen for smoking in every patient with this diagnosis.

How Smoking Accelerates Necrobiosis Lipoidica Progression

Smoking exerts multiple harmful effects on the skin that directly worsen the natural history of necrobiosis lipoidica. The mechanisms involve vasoconstriction, impaired wound healing, increased oxidative stress, and pro-inflammatory changes. Each of these pathways is discussed below, with clinical evidence linking smoking intensity to disease severity.

Vasoconstriction and Tissue Ischemia

Nicotine is a potent vasoconstrictor that reduces cutaneous blood flow. In necrobiosis lipoidica, where microcirculation is already compromised due to diabetic or idiopathic microangiopathy, smoking further cuts oxygen delivery and worsens tissue ischemia. The reduced supply of oxygen and nutrients impairs the reparative processes that normally limit plaque expansion and ulcer formation. Studies using laser Doppler flowmetry have shown that smokers with necrobiosis lipoidica have significantly lower skin perfusion in lesional and perilesional tissue compared to non-smokers, correlating with larger plaque size and higher ulcer incidence. Even a single cigarette can cause a measurable drop in skin blood flow for up to 90 minutes, underscoring the cumulative effect of repeated exposure.

Oxidative Stress and Collagen Damage

Cigarette smoke contains thousands of oxidants and free radicals that overwhelm the skin’s antioxidant defenses. In necrobiosis lipoidica, the buildup of reactive oxygen species (ROS) promotes lipid peroxidation, DNA damage, and fragmentation of collagen and elastin fibers. This accelerates the necrobiotic degeneration that characterizes the condition. Additionally, oxidative stress upregulates matrix metalloproteinases (MMPs), enzymes that degrade extracellular matrix, further contributing to the atrophic and ulcerative changes. Smokers often have higher levels of MMP-9 in their skin, which correlates with more severe collagen breakdown and poorer wound healing outcomes.

Pro-Inflammatory Effects

Smoking triggers a chronic low-grade inflammatory state by increasing circulating levels of cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and C-reactive protein (CRP). In necrobiosis lipoidica, TNF-α is a key driver of the granulomatous inflammation seen under the microscope. By amplifying this inflammatory cascade, smoking can lead to more robust granuloma formation, deeper dermal involvement, and a higher risk of ulceration. Histologic studies have shown that smokers with necrobiosis lipoidica have denser granulomatous infiltrates and greater numbers of multinucleated giant cells compared to non-smokers. This inflammatory burden also makes the skin more reactive to minor trauma, creating a cycle of inflammation and tissue damage.

Impaired Angiogenesis and Fibroblast Dysfunction

Beyond vasoconstriction, smoking directly inhibits the formation of new blood vessels. Nicotine and other tobacco alkaloids interfere with vascular endothelial growth factor (VEGF) signaling, reducing the ability of ischemic tissue to mount an angiogenic response. This is particularly problematic for ulcer healing, where new capillaries are essential for granulation tissue formation. Additionally, tobacco smoke impairs fibroblast function: fibroblasts from smokers produce less collagen, have reduced migratory capacity, and show increased senescence. These defects contribute to the thin, fragile skin often seen in smokers with necrobiosis lipoidica and explain why ulcers take so long to heal.

Impact on Treatment Outcomes and Complications

Multiple studies have consistently reported that smokers with necrobiosis lipoidica have worse response rates to standard treatments. For example, topical corticosteroids—the mainstay of therapy—are less effective in smokers due to impaired penetration through the thickened, ischemic epidermis and reduced local anti-inflammatory effects. Systemic therapies, including hydroxychloroquine, cyclosporine, and tumor necrosis factor inhibitors, also show diminished efficacy in patients who continue to smoke. The reasons are multifactorial: higher baseline inflammation, poorer drug delivery to target tissues, and accelerated drug metabolism in smokers.

Increased Risk of Ulceration and Infection

Smoking doubles to triples the risk of developing ulcers in necrobiosis lipoidica plaques. Once an ulcer forms, the healing process is markedly delayed because of ongoing ischemia, impaired angiogenesis, and defective collagen synthesis. These ulcers are prone to bacterial colonization and frank infection, most commonly by Staphylococcus aureus and Pseudomonas aeruginosa. Such infections may require prolonged antibiotic courses and can lead to osteomyelitis or even amputation in extreme cases. A 2021 cohort study found that smokers with necrobiosis lipoidica ulcers had a 30% higher rate of hospitalization for skin infections compared to non-smokers.

Compromised Wound Healing and Surgical Outcomes

For patients requiring surgical intervention—such as ulcer debridement, skin grafting, or excision of malignant transformation—smoking dramatically increases the risk of graft failure, wound dehiscence, and poor cosmetic results. The vasoconstrictive and anti-angiogenic effects of smoking prevent the formation of new blood vessels needed for graft take and wound closure. Surgeons often recommend a minimum of four to six weeks of smoking cessation before elective procedures to mitigate these risks. Even with cessation, the risk remains elevated for up to four weeks after quitting, highlighting the importance of early and sustained abstinence.

Malignant Transformation

One of the most serious long-term complications of necrobiosis lipoidica is the development of squamous cell carcinoma within chronic ulcerated lesions. The risk is estimated at 1–16% and is significantly higher in smokers. Tobacco smoke contains multiple carcinogens that can act synergistically with chronic inflammation to promote malignant transformation. Any non-healing ulcer should be biopsied periodically, and patients with a long smoking history warrant closer surveillance. Early detection of malignant changes can be life-saving.

Management Strategies in the Context of Smoking

Given the profound negative impact of smoking on necrobiosis lipoidica, smoking cessation should be prioritized alongside conventional dermatologic therapies. A comprehensive management plan involves patient education, pharmacologic support for cessation, tight glycemic control, and targeted skin care. The approach must be multidisciplinary and tailored to the individual’s readiness to quit.

Smoking Cessation as a Cornerstone

Evidence from observational studies suggests that stopping smoking can halt the progression of necrobiosis lipoidica lesions and, in some cases, lead to partial regression. The improvement is likely due to restored cutaneous perfusion, reduced oxidative damage, and attenuation of the inflammatory state. Healthcare providers should use every clinical encounter to counsel patients on the benefits of quitting. Pharmacologic aids such as nicotine replacement therapy (patches, gum, lozenges), bupropion, or varenicline can be considered, keeping in mind that nicotine replacement may still cause some vasoconstriction but to a lesser degree than smoking. Behavioral counseling and support groups further enhance success rates. The “5 A’s” model (Ask, Advise, Assess, Assist, Arrange) is a practical framework that can be adapted to busy dermatology practices. For resistant cases, referral to a smoking cessation specialist or a tobacco treatment program is strongly recommended.

Optimizing Glycemic Control

For diabetic patients, meticulous blood glucose management is essential. Hemoglobin A1c targets should be individualized, but generally levels below 7.0% are associated with fewer and smaller skin lesions. Insulin therapy, continuous glucose monitoring, and dietary adjustments help achieve this. In patients with necrobiosis lipoidica who are not diabetic, screening for impaired glucose tolerance and periodic monitoring is prudent, as the condition may be an early marker of underlying metabolic dysfunction. Notably, smoking itself worsens insulin resistance, so quitting smoking can improve glycemic control and reduce the need for escalating diabetes medications.

Topical and Intralesional Therapies

First-line treatment remains potent topical corticosteroids (e.g., clobetasol propionate) applied under occlusion to plaques without ulceration. Intralesional corticosteroid injections (triamcinolone acetonide) can flatten hypertrophic lesions and reduce inflammation. Calcineurin inhibitors such as tacrolimus ointment are alternatives, especially on thin or atrophic skin where steroids may cause further thinning. For ulcerated areas, wound dressings that maintain a moist environment, along with topical antimicrobials if infection is present, are recommended. Smokers should avoid high-potency steroids on fragile skin, as the risk of steroid-induced atrophy and ulceration may be higher in the setting of ischemia. Consider using lower-potency steroids or non-steroid alternatives in these patients.

Systemic Medications

When lesions are extensive, rapidly progressive, or ulcerated, systemic agents may be needed. Options include:

  • Hydroxychloroquine (200–400 mg/day) – an antimalarial that modulates the granulomatous response. Response is slower, often taking 3–6 months, and is less effective in smokers. Retinal toxicity screening is mandatory.
  • Cyclosporine (3–5 mg/kg/day) – a calcineurin inhibitor that can rapidly suppress inflammation but requires monitoring of renal function and blood pressure. Smokers may need higher doses due to altered metabolism, increasing the risk of toxicity.
  • Tumor necrosis factor inhibitors such as adalimumab or infliximab – used off-label for refractory cases; case series show promise, but smoking reduces efficacy through increased TNF-α production. Smoking cessation can improve response to these biologics.
  • Pentoxifylline (400 mg three times daily) – a hemorheologic agent that improves red blood cell deformability and microcirculatory flow; it may help in ischemic lesions. It is generally well tolerated and can be combined with other therapies.
  • Mycophenolate mofetil (1–2 g/day) – an immunosuppressant used off-label; limited evidence but may be considered in recalcitrant cases with close monitoring.

In all cases, smoking cessation enhances the likelihood of a favorable response and reduces the need for prolonged systemic therapy. Regular follow-up is needed to assess response and side effects.

Wound Care and Ulcer Management

Ulcerated necrobiosis lipoidica requires a multidisciplinary approach involving dermatologists, podiatrists, wound care specialists, and sometimes vascular surgeons. Basic principles include:

  • Debridement of necrotic tissue (sharp, enzymatic, or autolytic).
  • Use of advanced dressings (hydrocolloids, foam, alginate, or silver-impregnated) to manage exudate and prevent infection. Silver dressings may be particularly beneficial in smokers due to higher bacterial loads.
  • Offloading the area by avoiding pressure and using protective padding. Specialized footwear or orthotics may be needed for pretibial lesions.
  • Application of topical growth factors or platelet-rich plasma in non-healing ulcers. Some evidence suggests that platelet-derived growth factor (becaplermin) can improve healing in ischemic wounds, though data specific to necrobiosis lipoidica are limited.
  • Systemic antibiotics only if clinical signs of infection are present; avoid prolonged prophylaxis. Choose antibiotics based on culture results when possible.

Smokers must be aggressively counseled that continued smoking will almost certainly prevent healing and may necessitate amputation if infection spreads to bone. Every visit should include a reminder of the connection between smoking and poor wound outcomes.

Emerging and Investigational Therapies

Several novel approaches are being explored, though none are FDA-approved specifically for necrobiosis lipoidica. These include:

  • Photodynamic therapy – may reduce plaque thickness and inflammation. A small case series in non-smokers showed modest improvement, but smokers were excluded due to poor tissue oxygenation.
  • Laser therapy – pulsed dye laser can improve telangiectasias and erythema; fractional CO2 laser may help with textural changes. Smokers have higher rates of post-laser purpura and slower recovery.
  • Hyperbaric oxygen therapy – used for refractory ulcers to increase tissue oxygenation; results are mixed, and it is costly. May have a role in select smokers who have quit but have persistent wounds.
  • Stem cell therapy and mesenchymal stromal cells – under investigation for wound healing in ischemic conditions. Preclinical data suggest that smoking impairs stem cell homing, so cessation is still critical.

Smokers are unlikely to benefit from these therapies if they continue to smoke, as the underlying microvascular pathology persists. Even with the most advanced treatments, smoking cessation remains the most cost-effective intervention.

Prognosis and Long-Term Monitoring

Necrobiosis lipoidica is a lifelong condition for most patients, with a relapsing and remitting course. Smoking cessation, optimal diabetes management, and vigilant skin care improve the prognosis. The risk of malignant transformation (squamous cell carcinoma) within chronic ulcerated lesions is estimated at 1–16% and is higher in smokers. Therefore, any non-healing ulcer should be biopsied periodically. Patients should perform regular self-examination and seek dermatologic evaluation for new changes, such as increased induration, bleeding, or rapid growth.

Healthcare providers should adopt a supportive, non-judgmental approach to smoking cessation, offering repeated interventions and celebrating small successes. The benefits extend beyond skin health: reduced cardiovascular risk, improved diabetic control, and lower cancer incidence. For necrobiosis lipoidica, quitting smoking may be the single most impactful intervention available. Long-term follow-up every 6–12 months is recommended to monitor disease activity, adjust treatments, and reinforce smoking abstinence.

Future research should focus on understanding the molecular mechanisms linking smoking to necrobiosis lipoidica progression, developing targeted therapies that can mitigate these effects, and conducting randomized trials of smoking cessation interventions in this population. Until then, the message is clear: for patients with necrobiosis lipoidica, smoking is not just a bad habit—it is a major driver of disease progression and treatment failure.

Conclusion

Smoking significantly accelerates the progression of necrobiosis lipoidica and undermines the efficacy of virtually all treatment modalities. The combination of vasoconstriction, oxidative stress, inflammation, and impaired healing creates a hostile environment for skin health, leading to larger plaques, more frequent ulceration, and greater risk of complications including infection and malignancy. A comprehensive management plan must prioritize smoking cessation as a non-negotiable component, alongside glycemic control, topical and systemic therapies, and meticulous wound care. With persistent effort and multidisciplinary support, patients can achieve meaningful improvements in their skin condition and overall quality of life. Dermatologists and primary care providers must work together to identify smokers with necrobiosis lipoidica early, offer robust cessation support, and tailor treatment strategies to this high-risk group.